A number of new treatment options have recently emerged for patients with CLL, including inhibitors of Bruton's tyrosine kinase (ibrutinib) and phosphatidyl‐inositol 3‐kinase (idelalisib).2 In our study, five patients had been treated with ibrutinib. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.